Biotech

The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) combinations. The belantamab mafodotin combinations were evaluated in...

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) shares crashed 42.74% to $0.67 in after-hours trading on Friday after the company announced its voluntary delisting from the Nasdaq Capital Market. Check out how BCLI stock is trading here. What Happened: The biotechnology firm received formal...

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday. Eliquis is a blood-thinning medication that reduces blood clotting and...

Editor’s Note: The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title. Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after the company issued an after-hours update on ongoing label expansion efforts for Elevidys, its approved gene therapy for Duchenne muscular dystrophy. The U.S Food and Drug Administration (FDA) has requested that the...

22nd Century Group Inc. (NASDAQ:XXII) stock experienced a surge of 75.76% in after-hours trading on Wednesday. What Happened: The stock of 22nd Century Group, a biotechnology company that specializes in tobacco, surged $8.05, marking a 75.76% rise in after-hours trading on Wednesday. See Also:...

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measures. What To Know: After the market close on Wednesday, Sarepta Therapeutics introduced a strategic restructuring plan that...

The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New analysis reveals that states are losing billions in Medicaid rebates due to ineligible claims on...

The Division of Hepatology and Nutrition of the U.S. Food and Drug Administration lifted the partial clinical hold on Kezar Life Sciences Inc.‘s (NASDAQ:KZR) completed PORTOLA Phase 2a trial evaluating zetomipzomib in autoimmune hepatitis (AIH). AIH is a chronic liver disease in which the...

Klotho Neurosciences, Inc. (NASDAQ:KLTO) announced on Wednesday that it has received notification from Nasdaq that KLTO stock has full compliance with all continued listing requirements and will remain listed and traded on the Nasdaq Stock Market What To Know: Klotho has regained compliance with...

On Wednesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program. The trial showed that anselamimab, a light chain depleter antibody, did not achieve statistical significance for the primary endpoint compared to...

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68. The pharmaceutical giant reported sales of $23.74 billion, up 5.8% year over year and beating the consensus of...

Polyrizon Ltd (NASDAQ:PLRZ) saw a dip in its stock value during after-hours trading on Wednesday. What Happened: The after-hours price of Polyrizon’s stock was $0.92, marking a 12.02% dip from the previous day’s closing price of $1.04. This follows a regular trading session surge of 52....

Shares of Longevity Health Holdings Inc (NASDAQ:XAGE) surged on Tuesday afternoon following the announcement of its definitive merger agreement with plasma collection leader True Health Inc. What To Know: The all-stock transaction will see the combined entity continue trading on Nasdaq under the...

Kairos Pharma, Ltd. (NYSE:KAPA) stock is trading higher on Tuesday, with a strong session volume of 221 million compared to the average volume of 874.3K as per data from Benzinga Pro. The company on Tuesday released safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in...